Aerie Launches Rhopressa in US as Treatment for Lowering IOP

May 4, 2018: By Jon Swedien

Aerie Pharmaceuticals has launched Rhopressa in the US, the Durham, North Carolina, company announced April 30.

Aerie forecasts the open-angle glaucoma and ocular hypertension treatment will net $20 million to $30 million in 2018, the company said in March.

Rhopressa (netarsudil ophthalmic solution) 0.02% gained US FDA approval in December 2017. It is a rho-associated protein kinase (rho kinase, or ROCK) inhibitor, a new class of medications proposed to lower intraocular pressure (IOP) by directly increasing trabecular outflow. The eye drop is administered once daily.

The company’s national sales force is now providing product information and samples to physicians, said Aerie Chairman and CEO Vicente Anido Jr., PhD.

The company said it expects to gain preferred formulary coverage for the majority of commercial payers for Rhopressa by late 2018, with most of the Medicare Part D coverage expected to start in 2019.

Aerie is also developing a second IOP-lowering product candidate—Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%. It is also a once-daily eye drop.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT